Specially selected strains of lactobacilli may positively shift the skin microbiome and reduce acne lesions, says a new study from Belgium that deepens our knowledge of skin microbiome modulation.
Sanofi is to acquire Origimm Biotechnology in a move that gives the pharma giants a candidate to develop a first-in-class acne vaccine, which targets the skin microbiome and bacterial antigens that cause the skin condition.
British pharma company GlaxoSmithKline (GSK) are to pair up with Eligo Bioscience in a deal potentially worth €185m ($224m) that sees the firms target the microbiome to reduce the risk of developing acne.
